GlassScriptPhysician profile
Amy Solomon
NPI 1407842461
$3,883.94
in general payments reported to CMS, 2019-2025
34 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $240 · 2021: $387 · 2022: $377 · 2023: $454 · 2024: $524 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427 · Consulting Fee: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.40 |
| Consulting Fee | $875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Winter & Ibe Gmbh | $875.00 | 2025 | Endoeye Flex Deflectable Videoscope |
| Abbvie INC. | $615.43 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Therapeuticsmd, INC. | $299.52 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $261.18 | 2022-2025 | |
| Pfizer INC. | $203.57 | 2020-2024 | |
| Myovant Sciences INC. | $174.89 | 2021-2022 | |
| Evofem Biosciences, INC. | $159.96 | 2020-2021 | |
| Millicent US INC | $130.98 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Astellas Pharma US INC | $125.01 | 2022-2025 | Veozah |
| Sumitomo Pharma America, INC. | $107.88 | 2023-2024 | Myfembree |
| Hologic Sales and Service, LLC | $102.71 | 2023-2025 | Novasure, Myosure Tissue Removal Device, Coolseal Generator |
| Organon LLC | $85.56 | 2022-2025 | Jada System, Nexplanon |
| Exeltis, USA INC. | $78.89 | 2021-2025 | Slynd |
| Novo Nordisk INC | $68.58 | 2022-2024 | Wegovy |
| Sage Therapeutics, LLC | $68.15 | 2022-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $49.83 | 2021-2022 | |
| Agile Therapeutics, INC. | $49.39 | 2022-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $48.26 | 2023-2025 | |
| Roche Diagnostics Corporation | $42.60 | 2021-2022 | |
| Meditrina | $42.22 | 2023-2024 | |
| Mimedx Group, INC. | $35.37 | 2025 | |
| Coopersurgical, INC. | $35.24 | 2019-2024 | Paragard T 380a |
| Astrazeneca Pharmaceuticals LP | $29.35 | 2024 | Lynparza |
| Lupin INC. | $25.22 | 2019-2020 | |
| Monaghan Medical Corporation | $22.02 | 2023 | Aerochamber |
| Minerva Surgical, INC | $19.16 | 2022 | |
| Amag Pharmaceuticals, INC. | $18.50 | 2019 | |
| Lilly USA, LLC | $18.38 | 2025 | Zepbound |
| Mylan Pharmaceuticals INC. | $17.53 | 2019 | |
| Intercept Pharmaceuticals, INC. | $17.40 | 2024 | |
| Exact Sciences Corporation | $15.91 | 2025 | Cologuard Collection Kit |
| Scynexis, INC. | $14.75 | 2022 | |
| Amgen INC. | $13.51 | 2024 | Prolia, Evenity |
| Vertical Pharmaceuticals, LLC | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.